Photo Nature Travel / Shutterstock.com

10 July 2025NewsAmericasMuireann Bolger

J&J fends off generic schizophrenia drug bids

Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

15 April 2025 Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna.

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

More on this story

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

15 April 2025 Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna.

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

More on this story

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

15 April 2025 Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna.

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

More features

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC

UKIPO rejects Boehringer’s SPC for horse inhaler

WilmerHale gains partner with ‘deep expertise’

Bayer, Orion take on Indian generic over $117bn drug

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office